Indicate by a check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

This Quarterly Report on Form 10-Q contains forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “should” and similar expressions or the negative versions thereof and which also may be identified by their context. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. The Company assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following: Meridian’s continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, and its ability to effectively sell such products. While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis. Meridian relies on proprietary, patented and licensed technologies, and the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products. The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. The Company cannot predict the possible impact of U.S. healthcare legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Healthcare and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof, and any similar initiatives in other countries on its results of operations. In addition to the factors described in this paragraph, Part I, Item 1A Risk Factors of our Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company.


	Three Months Ended					Six Months Ended
	March 31,					March 31,					Three Months Ended June 30,						Nine Months Ended June 30,
	2014			2013		2014			2013		2014			2013			2014			2013
NET REVENUES	$	50,134		$	47,265	$	94,928		$	92,616	$	47,212		$	47,108		$	142,140		$	139,724
COST OF SALES		18,541			16,522		35,328			33,077		17,970			16,477			53,298			49,554

GROSS PROFIT		31,593			30,743		59,600			59,539		29,242			30,631			88,842			90,170

OPERATING EXPENSES
Research and development		3,186			2,811		6,039			5,328		3,146			2,711			9,185			8,039
Selling and marketing		6,461			5,471		12,538			11,164		6,249			5,440			18,787			16,604
General and administrative		6,280			7,208		13,731			14,703		6,715			6,781			20,446			21,484

Total operating expenses		15,927			15,490		32,308			31,195		16,110			14,932			48,418			46,127

OPERATING INCOME		15,666			15,253		27,292			28,344		13,132			15,699			40,424			44,043
OTHER INCOME (EXPENSE)
Interest income		6			19		10			26		5			12			15			38
Other, net		(28	)		257		(248	)		385		(257	)		(160	)		(505	)		225

Total other income (expense)		(22	)		276		(238	)		411		(252	)		(148	)		(490	)		263

EARNINGS BEFORE INCOME TAXES		15,644			15,529		27,054			28,755		12,880			15,551			39,934			44,306
INCOME TAX PROVISION		5,344			5,280		9,328			10,032		4,045			5,392			13,373			15,424

NET EARNINGS	$	10,300		$	10,249	$	17,726		$	18,723	$	8,835		$	10,159		$	26,561		$	28,882

BASIC EARNINGS PER COMMON SHARE	$	0.25		$	0.25	$	0.43		$	0.45	$	0.21		$	0.25		$	0.64		$	0.70
DILUTED EARNINGS PER COMMON SHARE	$	0.24		$	0.24	$	0.42		$	0.45	$	0.21		$	0.24		$	0.63		$	0.69
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC		41,471			41,266		41,434			41,188		41,478			41,304			41,445			41,209
EFFECT OF DILUTIVE STOCK OPTIONS AND RESTRICTED SHARES AND UNITS		676			681		686			642		618			679			669			654

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - DILUTED		42,147			41,947		42,120			41,830		42,096			41,983			42,114			41,863

ANTI-DILUTIVE SECURITIES:
Common share options and restricted shares and units		168			262		137			295		337			256			161			295

DIVIDENDS DECLARED PER COMMON SHARE	$	0.20		$	—	$	0.39		$	0.38	$	0.20		$	0.19		$	0.59		$	0.57

The accompanying notes are an integral part of these condensed consolidated financial statements.


											Three Months Ended				Nine Months Ended
	Three Months Ended March 31,					Six Months Ended March 31,					June 30,				June 30,
	2014		2013			2014		2013			2014		2013		2014		2013
NET EARNINGS	$	10,300	$	10,249		$	17,726	$	18,723		$	8,835	$	10,159	$	26,561	$	28,882
Foreign currency translation adjustment		337		(1,217	)		1,060		(971	)		361		154		1,421		(817	)

COMPREHENSIVE INCOME	$	10,637	$	9,032		$	18,786	$	17,752		$	9,196	$	10,313	$	27,982	$	28,065

The accompanying notes are an integral part of these condensed consolidated financial statements.


Six Months Ended March 31,	2014			2013
Nine Months Ended June 30,							2014			2013
CASH FLOWS FROM OPERATING ACTIVITIES
Net earnings	$	17,726		$	18,723		$	26,561		$	28,882
Non-cash items included in net earnings:
Depreciation of property, plant and equipment		1,756			1,666			2,634			2,522
Amortization of intangible assets		1,042			1,165			1,549			1,715
Amortization of deferredillumigene instrument costs		864			746			1,281			1,131
Stock-based compensation		2,157			1,573			2,662			1,984
Deferred income taxes		(31	)		(278	)		(438	)		(1,356	)
Loss on disposition and write-down of fixed assets and other assets		—			10			22			30
Change in current assets		(6,656	)		477			(6,804	)		(3,125	)
Change in current liabilities		(3,143	)		(1,116	)		(4,055	)		951
Other, net		(159	)		(586	)		199			(220	)

Net cash provided by operating activities		13,556			22,380			23,611			32,514

CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property, plant and equipment		(2,573	)		(1,408	)		(3,968	)		(2,193	)
Purchases of intangible assets		(1,677	)		(20	)		(1,687	)		(20	)

Net cash used for investing activities		(4,250	)		(1,428	)		(5,655	)		(2,213	)

CASH FLOWS FROM FINANCING ACTIVITIES
Dividends paid		(16,169	)		(15,652	)		(24,464	)		(23,500	)
Proceeds and tax benefits from exercises of stock options		540			2,055			629			2,094

Net cash used for financing activities		(15,629	)		(13,597	)		(23,835	)		(21,406	)

Effect of Exchange Rate Changes on Cash and Equivalents		254			(354	)		882			(125	)

Net (Decrease) Increase in Cash and Equivalents		(6,069	)		7,001			(4,997	)		8,770
Cash and Equivalents at Beginning of Period		44,282			31,593			44,282			31,593

Cash and Equivalents at End of Period	$	38,213		$	38,594		$	39,285		$	40,363

The accompanying notes are an integral part of these condensed consolidated financial statements.


	March 31,		September 30,
	2014		2013		June 30, 2014		September 30, 2013
	(Unaudited)				(Unaudited)
CURRENT ASSETS
Cash and equivalents	$	38,213	$	44,282	$	39,285	$	44,282
Accounts receivable, less allowances of $206 and $233		26,799		26,183
Accounts receivable, less allowances of $214 and $233						25,806		26,183
Inventories		38,133		34,835		37,605		34,835
Prepaid expenses and other current assets		6,454		4,643		6,423		4,643
Deferred income taxes		4,352		4,145		4,331		4,145

Total current assets		113,951		114,088		113,450		114,088

PROPERTY, PLANT AND EQUIPMENT, at Cost
Land		1,186		1,183		1,184		1,183
Buildings and improvements		26,900		26,848		26,930		26,848
Machinery, equipment and furniture		39,315		38,502		39,225		38,502
Construction in progress		2,190		554		2,982		554

Subtotal		69,591		67,087		70,321		67,087
Less: accumulated depreciation and amortization		42,702		40,996		43,014		40,996

Net property, plant and equipment		26,889		26,091		27,307		26,091

OTHER ASSETS
Goodwill		23,507		23,115		23,826		23,115
Other intangible assets, net		8,841		8,057		8,472		8,057
Restricted cash		1,000		1,000		1,000		1,000
Deferredillumigene instrument costs, net		2,719		3,270		2,982		3,270
Deferred income taxes		930		823		1,380		823
Other assets		318		304		346		304

Total other assets		37,315		36,569		38,006		36,569

TOTAL ASSETS	$	178,155	$	176,748	$	178,763	$	176,748

The accompanying notes are an integral part of these condensed consolidated financial statements.


	March 31,		September 30,
	2014		2013		June 30, 2014		September 30, 2013
	(Unaudited)				(Unaudited)
CURRENT LIABILITIES
Accounts payable	$	7,829	$	5,592	$	6,416	$	5,592
Accrued employee compensation costs		3,586		9,670		3,914		9,670
Other accrued expenses		5,570		5,462		5,738		5,462
Income taxes payable		838		979		875		979

Total current liabilities		17,823		21,703		16,943		21,703

COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS’ EQUITY
Preferred stock, no par value, 1,000,000 shares authorized, none issued		—		—		—		—
Common shares, no par value, 71,000,000 shares authorized, 41,555,653 and 41,517,839 shares issued, respectively		—		—
Common shares, no par value, 71,000,000 shares authorized, 41,564,271 and 41,517,839 shares issued, respectively						—		—
Additional paid-in capital		110,082		107,412		110,669		107,412
Retained earnings		48,445		46,888		48,985		46,888
Accumulated other comprehensive income		1,805		745		2,166		745

Total shareholders’ equity		160,332		155,045		161,820		155,045

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$	178,155	$	176,748	$	178,763	$	176,748

The accompanying notes are an integral part of these condensed consolidated financial statements.

Condensed Consolidated Statement of Changes in Shareholders’ Equity (Unaudited)


	Common Shares Issued		Additional Paid-In Capital		Retained Earnings			Accumulated Other Comprehensive Income (Loss)		Total Shareholders’ Equity			Common Shares Issued			Additional Paid-In Capital		Retained Earnings			Accumulated Other Comprehensive Income		Total Shareholders’ Equity
Balance at September 30, 2013		41,518	$	107,412	$	46,888		$	745	$	155,045			41,518		$	107,412	$	46,888		$	745	$	155,045
Cash dividends paid		—		—		(16,169	)		—		(16,169	)		—			—		(24,464	)		—		(24,464	)
Exercise of stock options		36		513		—			—		513			44			595		—			—		595
Conversion of restricted stock units		2		—		—			—		—			3			—		—			—		—
Cancellation of restricted shares														(1	)		—		—			—		—
Stock compensation expense		—		2,157		—			—		2,157			—			2,662		—			—		2,662
Net earnings		—		—		17,726			—		17,726			—			—		26,561			—		26,561
Foreign currency translation adjustment		—		—		—			1,060		1,060			—			—		—			1,421		1,421

Balance at March 31, 2014		41,556	$	110,082	$	48,445		$	1,805	$	160,332
Balance at June 30, 2014														41,564		$	110,669	$	48,985		$	2,166	$	161,820

The accompanying notes are an integral part of these condensed consolidated financial statements.

The interim condensed consolidated financial statements are unaudited and are prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information, and the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the interim financial statements include all normal adjustments and disclosures necessary to present fairly the Company’s financial position as of ~~March 31,~~June 30, 2014, the results of its operations for the three and ~~six~~nine month periods ended ~~March 31,~~June 30, 2014 and 2013, and its cash flows for the ~~six~~nine month periods ended ~~March 31,~~June 30, 2014 and 2013. These statements should be read in conjunction with the consolidated financial statements and footnotes thereto included in the Company’s fiscal 2013 Annual Report on Form 10-K. Financial information as of September 30, 2013 has been derived from the Company’s audited consolidated financial statements.

The results of operations for interim periods are not necessarily indicative of the results to be expected for the year.

Revenue is generally recognized from sales when product is shipped and title has passed to the customer. Revenue for the Diagnostics segment is reduced at the date of sale for product price adjustments due certain distributors under local contracts. Management estimates accruals for distributor price adjustments based on local contract terms, sales data provided by distributors, estimates of inventories of certain of our products held by distributors, historical statistics, current trends, and other factors. Changes to the accruals are recorded in the period that they become known. Such accruals were ~~$4,207~~$4,074 at ~~March 31,~~June 30, 2014 and $3,866 at September 30, 2013, and have been netted against accounts receivable.

Revenue for our Diagnostics segment includes revenue for ourillumigene^®molecular test system. This system includes an instrument, instrument accessories and test kits. In markets where the test system is sold via multiple deliverable arrangements (i.e., the United States, Australia, Belgium, France, Holland and Italy), the cost of the instrument and instrument accessories are deferred upon placement at a customer and amortized on a straight-line basis into cost of sales over the expected utilization period, generally three years.

We evaluate whether each deliverable in the arrangement is a separate unit of accounting. The significant deliverables are an instrument, instrument accessories (e.g., printer) and test kits. An instrument and instrument accessories are delivered to the customer prior to the start of the customer utilization period, in order to accommodate customer set-up and installation. There isde minimis consideration received from the customer at the time of instrument placement. We have determined that the instrument and instrument accessories are not a separate unit of accounting because such equipment can only be used to process and read the results from ourillumigene diagnostic tests (i.e., our instrument and test kits function together to deliver a diagnostic test result), and therefore the instrument and instrument accessories do not have standalone value to the customer. Consequently, there is no revenue allocated to the placement of the instrument and instrument accessories. Test kits are delivered to the customer over the utilization period of the instrument, which we estimate has a useful life of three years. Our average customer contract period, including estimated renewals, is at least equal to the estimated three-year utilization period. Revenue for the sale of test kits is recognized upon shipment and transfer of title to the customers.

In markets where the test system is not sold via multiple deliverable arrangements (i.e., countries other than the United States, Australia, Belgium, France, Holland and Italy), the cost of the instrument and instrument accessories is charged to cost of sales at the time of shipment and transfer of title to the customer. Revenue for the sales of instruments and instrument accessories and test kits is recognized upon shipment and transfer of title to the customers. In these markets, ourillumigenemolecular test system is sold to independent distributors who inventory the instruments, instrument accessories and test kits for resale to end-users.

Our products are generally not subject to a customer right of return except for product recall events under the rules and regulations of the Food and Drug Administration or equivalent agencies outside the United States. In this circumstance, the costs to replace affected products would be accrued at the time a loss was probable and estimable.

Life Science revenue for contract services may come from research and development services or manufacturing services, including process development work, or a combination of both. Revenue is recognized based on each of the deliverables in a given arrangement having distinct and separate customer pricing. Depending on the nature of the arrangement, revenue is recognized as services are performed and billed, upon completion and acceptance by the customer, or upon delivery of product and acceptance by the customer.

Trade accounts receivable are recorded in the accompanying Condensed Consolidated Balance Sheets at invoiced amounts less provisions for distributor price adjustments under local contracts and doubtful accounts. The allowance for doubtful accounts represents our estimate of probable credit losses and is based on historical write-off experience. The allowance for doubtful accounts and related metrics, such as days’ sales outstanding, are reviewed monthly. Accounts with past due balances over 90 days are reviewed individually for collectibility. Customer invoices are charged off against the allowance when we believe it is probable that the invoices will not be paid.

As reflected in the accompanying Condensed Consolidated Statements of Comprehensive Income, our comprehensive income or loss is comprised of net earnings and foreign currency translation.

Assets and liabilities of foreign operations are translated using period-end exchange rates with gains or losses resulting from translation included as a separate component of comprehensive income or loss. Revenues and expenses are translated using exchange rates prevailing during the period. We also recognize foreign currency transaction gains and losses on certain assets and liabilities that are denominated in non-functional currencies. These gains and losses are included in other income and expense in the accompanying Condensed Consolidated Statements of Operations.

The provision for income taxes includes federal, foreign, state and local income taxes currently payable and those deferred because of temporary differences between income for financial reporting and income for tax purposes. We prepare estimates of permanent and temporary differences between income for financial reporting purposes and income for tax purposes. These differences are adjusted to actual upon filing of our tax returns, typically occurring in the third and fourth quarters of the current fiscal year for the preceding fiscal year’s estimates.

We account for uncertain tax positions using a benefit recognition model with a two-step approach: (i) a more-likely-than-not recognition criterion; and (ii) a measurement attribute that measures the position as the largest amount of tax benefit that is greater than 50% likely of being ultimately realized upon settlement. If it is not more likely than not that the benefit will be sustained on its technical merits, no benefit is recorded. We recognize accrued interest and penalties related to unrecognized tax benefits as a portion of our income tax provision in the Condensed Consolidated Statements of Operations.

In September 2013, the Internal Revenue Service issued Treasury Decision 9636, which enacted final tax regulations regarding the capitalization and expensing of amounts paid to acquire, produce, or improve tangible property. The regulations also include guidance regarding the retirement of depreciable property. The regulations are required to be effective in taxable years beginning on or after January 1, 2014, although taxpayers may choose to apply them in taxable years beginning on or after January 1, 2012. ~~The Company is currently assessing the impact~~Our adoption of ~~the final~~these regulations on ~~its~~October 1, 2014 is not expected to have a significant impact on the Company’s consolidated results of operations, cash flows or financial ~~statements.~~position.

We recognize compensation expense for all share-based awards made to employees, based upon the fair value of the share-based award on the date of the grant. Awards are expensed over their requisite service periods.


	March 31, 2014				September 30, 2013				June 30, 2014				September 30, 2013
	Cash and Equivalents		Other		Cash and Equivalents		Other		Cash and Equivalents		Other		Cash and Equivalents		Other
Overnight repurchase agreements	$	23,791	$	—	$	32,103	$	—	$	24,074	$	—	$	32,103	$	—

Cash on hand -
Restricted		—		1,000		—		1,000		—		1,000		—		1,000
Unrestricted		14,422		—		12,179		—		15,211		—		12,179		—

Total	$	38,213	$	1,000	$	44,282	$	1,000	$	39,285	$	1,000	$	44,282	$	1,000

In May 2014, FASB issued ASU No. 2014-09,Revenue from Contracts with Customers, which supersedes and replaces nearly all currently-existing U.S. GAAP revenue recognition guidance including related disclosure requirements. This guidance will be effective for the Company beginning October 1, 2017. The Company has not yet assessed the impact that adoption of this guidance will have on its financial statements.

Certain reclassifications have been made to the prior period financial statements to conform to the current fiscal period presentation. Such reclassifications had no impact on net earnings or shareholders’ equity.


	March 31, 2014		September 30, 2013		June 30, 2014		September 30, 2013
Raw materials	$	6,591	$	7,170	$	5,960	$	7,170
Work-in-process		5,989		8,585		10,457		8,585
Finished goods -*illumi*gene instruments		2,694		1,980		1,993		1,980
Finished goods - kits and reagents		22,859		17,100		19,195		17,100

Total	$	38,133	$	34,835	$	37,605	$	34,835

Meridian was formed in 1976 and functions as a fully-integrated research, development, manufacturing, marketing and sales organization with primary emphasis in the fields of in vitro diagnostics and life science. Our principal businesses are (i) the development, manufacture and distribution of diagnostic test kits primarily for gastrointestinal, viral, respiratory and parasitic infectious diseases; and (ii) the manufacture and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers, and the contract development and manufacture of proteins and other biologicals for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines.

In the fourth quarter of fiscal 2013, we aggregated our Diagnostics operating segments into a single reportable segment, thereby resulting in our reportable segments being Diagnostics and Life Science. The prior period information reflected herein has been conformed to the current period presentation.

The Diagnostics segment is headquartered in Cincinnati, Ohio, which also serves as the base of manufacturing operations and research and development. The Diagnostics segment has sales and distribution facilities in the United States, Europe and Australia. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany; and Sydney, Australia, and the sale and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells and bioresearch reagents domestically and abroad, including a sales and business development location in Singapore. The Life Science segment also includes the contract development and manufacture of cGMP clinical grade proteins and other biologicals for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines.

Amounts due from two Diagnostics distributor customers accounted for 15% and 17% of consolidated accounts receivable at ~~March 31,~~June 30, 2014 and September 30, 2013, respectively. Revenue from these two distributor customers accounted for ~~35%~~36% and ~~42%~~40% of the Diagnostics segment third-party revenue during the three months ended ~~March 31,~~June 30, 2014 and 2013, respectively, and 36% and ~~44%~~43% during the ~~six~~nine months ended ~~March 31,~~June 30, 2014 and 2013, respectively. In addition, approximately $3,400 and $3,500 of our accounts receivable at ~~both March 31,~~June 30, 2014 and September 30, 2013, respectively, is due from Italian hospital customers whose funding ultimately comes from the Italian government, representing 13% of consolidated accounts receivable in each of the respective periods.

Within our Life Science segment, two diagnostic manufacturing customers accounted for ~~23%~~15% and 18% of the segment’s third-party revenue during the three months ended ~~March 31,~~June 30, 2014 and 2013, respectively, and ~~17%~~16% and 18% during the ~~six~~nine months ended ~~March 31,~~June 30, 2014 and 2013, respectively.


	Diagnostics		Life Science		Eliminations(1)			Total			Diagnostics		Life Science		Eliminations(1)			Total
Three Months Ended March 31, 2014
Three Months Ended June 30, 2014										Three Months Ended June 30, 2014
Net revenues -
Third-party	$	37,061	$	13,073	$	—		$	50,134		$	35,168	$	12,044	$	—		$	47,212
Inter-segment		154		225		(379	)		—			99		374		(473	)		—
Operating income		12,301		3,306		59			15,666			10,526		2,676		(70	)		13,132
Goodwill (March 31, 2014)		1,250		22,257		—			23,507
Other intangible assets, net (March 31, 2014)		2,968		5,873		—			8,841
Total assets (March 31, 2014)		111,319		115,444		(48,608	)		178,155
Three Months Ended March 31, 2013
Goodwill (June 30, 2014)												1,250		22,576		—			23,826
Other intangible assets, net (June 30, 2014)												2,853		5,619		—			8,472
Total assets (June 30, 2014)												111,208		68,200		(645	)		178,763
Three Months Ended June 30, 2013
Net revenues -
Third-party	$	36,403	$	10,862	$	—		$	47,265		$	35,305	$	11,803	$	—		$	47,108
Inter-segment		105		350		(455	)		—			185		356		(541	)		—
Operating income		12,494		3,046		(287	)		15,253			12,296		3,543		(140	)		15,699
Goodwill (September 30, 2013)		1,250		21,865		—			23,115			1,250		21,865		—			23,115
Other intangible assets, net (September 30, 2013)		1,561		6,496		—			8,057			1,561		6,496		—			8,057
Total assets (September 30, 2013)		112,054		110,111		(45,417	)		176,748			111,719		65,393		(364	)		176,748
Six Months Ended March 31, 2014
Nine Months Ended June 30, 2014
Net revenues -
Third-party	$	71,898	$	23,030	$	—		$	94,928		$	107,066	$	35,074	$	—		$	142,140
Inter-segment		263		484		(747	)		—			362		858		(1,220	)		—
Operating income		21,685		5,567		40			27,292			32,211		8,243		(30	)		40,424
Six Months Ended March 31, 2013
Nine Months Ended June 30, 2013
Net revenues -
Third-party	$	72,072	$	20,544	$	—		$	92,616		$	107,377	$	32,347	$	—		$	139,724
Inter-segment		203		508		(711	)		—			388		864		(1,252	)		—
Operating income		23,834		4,680		(170	)		28,344			36,130		8,223		(310	)		44,043

Transactions between segments are accounted for at established intercompany prices for internal and management purposes, with all intercompany amounts eliminated in consolidation.

A summary of our acquired intangible assets subject to amortization, as of ~~March 31,~~June 30, 2014 and September 30, 2013 is as follows:


	March 31, 2014				September 30, 2013				June 30, 2014				September 30, 2013
	Gross Carrying Value		Accumulated Amortization		Gross Carrying Value		Accumulated Amortization		Gross Carrying Value		Accumulated Amortization		Gross Carrying Value		Accumulated Amortization
Manufacturing technologies, core products and cell lines	$	11,723	$	10,375	$	11,676	$	10,097	$	11,762	$	10,512	$	11,676	$	10,097
Trademarks, licenses and patents		6,474		2,481		4,748		2,130		6,543		2,663		4,748		2,130
Customer lists and supply agreements		12,481		8,981		12,353		8,493		12,584		9,242		12,353		8,493

	$	30,678	$	21,837	$	28,777	$	20,720	$	30,889	$	22,417	$	28,777	$	20,720

During the first quarter of fiscal 2014, we acquired the remaining licensing rights related to patents that are part of ourillumigene molecular technology for $1,638. These rights are being amortized over a weighted average period of approximately 8.5 years.

The actual aggregate amortization expense for these intangible assets was ~~$516~~$507 and ~~$585~~$550 for the three months ended ~~March 31,~~June 30, 2014 and 2013, respectively, and ~~$1,042~~$1,549 and ~~$1,165~~$1,715 for the ~~six~~nine months ended ~~March 31,~~June 30, 2014 and 2013, respectively. The estimated aggregate amortization expense for these intangible assets for each of the fiscal years through fiscal 2019 is as follows: remainder of fiscal 2014 – ~~$967,~~$482, fiscal 2015 – ~~$1,777,~~$1,797, fiscal 2016 – ~~$1,432,~~$1,451, fiscal 2017 – ~~$1,163,~~$1,177, fiscal 2018 – ~~$1,140~~$1,154 and fiscal 2019 – ~~$1,099.~~$1,113.

Refer to “Forward Looking Statements” following the Table of Contents in front of this Form 10-Q. In the discussion that follows, all dollar amounts are in thousands (both tables and text), except per share data.

Following is a discussion and analysis of the financial statements and other statistical data that management believes will enhance the understanding of Meridian’s financial condition, changes in financial condition and results of operations. This discussion should be read in conjunction with the financial statements and notes thereto beginning on page 1.

Net earnings for the ~~second~~third quarter of fiscal 2014 ~~increased less than 1%~~decreased 13% to ~~$10,300,~~$8,835, or ~~$0.24~~$0.21 per diluted share, from net earnings for the ~~second~~third quarter of fiscal 2013 of ~~$10,249,~~$10,159, or $0.24 per diluted share. This ~~increase~~decrease reflects the combined effects of slightly increased revenues, ~~slightly~~ decreased gross profit margins and ~~modestly~~ increased operating expenses. Consolidated revenues increased 6%less than 1% to ~~$50,134~~$47,212 for the ~~second~~third quarter of fiscal 2014 compared to the same period of the prior year.

Included within the ~~second~~third quarter 2014 results were revenues from ourillumigene^®molecular platform of products totaling ~~$9,853,~~$9,578, representing a ~~23%~~9% increase over the fiscal 2013 ~~second~~third quarter. Also contributing to the consolidated revenue increase were increased revenues in ourH. pylori focus product family and our respiratory product family, as well as in ~~both of~~ our Life Science segment’s ~~product lines (i.e.,~~ molecular component ~~and immunoassay component).~~product line. Serving to ~~partially~~substantially offset these revenue increases were decreased revenues in our largest diagnostic focus product family (C. difficile), our foodborne focus product family and our ~~respiratory~~Life Science segment’s immunoassay component product ~~family.~~line.

Revenues for the Diagnostics segment for the ~~second~~third quarter of fiscal 2014 ~~increased 2%~~decreased less than 1% compared to the ~~second~~third quarter of fiscal 2013, reflecting the following for each of our focus product families: 6%10% decline in ourC. difficile products, ~~11%~~9% growth in ourH. pylori products, and ~~1% growth~~5% decline in our foodborne products. In addition, we experienced ~~an 8% decline~~a 9% increase in revenues from our respiratory products, which include both molecular and immunoassay products, compared to the prior year fiscal ~~second~~third quarter. With ~~15%~~6% growth in its molecular component product sales and ~~24% growth~~a 1% decline in its immunoassay component product sales, revenues from our Life Science segment increased by ~~20%~~2% during the ~~second~~third quarter of fiscal 2014 compared to the ~~second~~third quarter of fiscal ~~2013, reflecting the effect of shipping certain orders during the fiscal 2014 second quarter that were delayed from the fiscal 2014 first quarter.~~2013.

For the ~~six~~nine month period ended ~~March 31,~~June 30, 2014, net earnings decreased 5%8% to ~~$17,726,~~$26,561, or ~~$0.42~~$0.63 per diluted share, from net earnings for the comparable fiscal 2013 period of ~~$18,723,~~$28,882, or ~~$0.45~~$0.69 per diluted share. This decrease reflects the combined effects of increased revenues, ~~slightly~~ decreased gross profit margins and modestly increased operating expenses, along with a $450 (pre-tax) negative effect from medical device tax that did not exist during the first quarter of fiscal 2013 (see discussion in Medical Device Tax below). Consolidated revenues increased 2% to ~~$94,928~~$142,140 for the first ~~six~~nine months of fiscal 2014 compared to the same period of the prior fiscal year.

Included within the ~~six~~nine month year-to-date fiscal 2014 results were revenues from ourillumigene molecular platform of products totaling ~~$18,348,~~$27,926, representing a ~~19%~~15% increase over the first ~~six~~nine months of fiscal 2013. Also contributing to the consolidated revenue increase were increased revenues in ourH. pylori focus product family, as well as in both of our Life Science segment’s business lines (i.e., molecular component and immunoassay component). Serving to substantially offset these revenue increases were decreased revenues in our largest diagnostic focus product family (C. difficile) and our respiratory product family.

During the first ~~six~~nine months of fiscal 2014, revenues for the Diagnostics segment decreased less than 1% from the comparable fiscal 2013 period, reflecting the following for each of our focus product families: 8%9% decline in ourC. difficile products, 10% growth in ourH. pylori products, and 1% ~~growth~~decline in our foodborne products. In addition, we experienced ~~a 13%~~an 8% decline in revenues from our respiratory products from the comparable fiscal 2013 period. With ~~16%~~12% growth in its molecular component product sales and ~~10%~~6% growth in its immunoassay component product sales, revenues from our Life Science segment increased by ~~12%~~8% during the ~~six~~nine months ended ~~March 31,~~June 30, 2014 over the comparable fiscal 2013 period.

Below are analyses of the Company’s revenue, provided for each of the following:

Our reportable segments are Diagnostics and Life Science. The Diagnostics segment is headquartered in Cincinnati, Ohio, which also serves as the base of manufacturing operations and research and development. The Diagnostics segment sells diagnostic test kits in the U.S. and Canada (“North America”); Europe, Middle East and Africa (“EMEA”); and other countries outside of North America and EMEA (rest of the world, or “ROW”). The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany; and Sydney, Australia, and the sale and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells and bioresearch reagents domestically and abroad, including a sales and business development location in Singapore. The Life Science segment also includes the contract development and manufacture of cGMP clinical grade proteins and other biologicals for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines.

Revenues for the Diagnostics segment, in the normal course of business, may be affected from quarter to quarter by buying patterns of major distributors, seasonality and strength of certain diseases, and foreign currency exchange rates. Revenues for the Life Science segment, in the normal course of business, may be affected from quarter to quarter by the timing and nature of arrangements for contract services work, which may have longer production

cycles than bioresearch reagents and bulk antigens and antibodies, as well as buying patterns of major customers, and foreign currency exchange rates. We believe that the overall breadth of our product lines serves to reduce the variability in consolidated revenues.


	Three Months Ended March 31,									Six Months Ended March 31,									Three Months Ended June 30,									Nine Months Ended June 30,
	2014			2013			Inc (Dec)			2014			2013			Inc (Dec)			2014			2013			Inc (Dec)			2014			2013			Inc (Dec)
Diagnostics -
Diagnostics-
North America	$	29,952		$	28,882			4	%	$	57,895		$	57,696			—	%	$	28,543		$	28,307			1	%	$	86,438		$	86,003			1	%
EMEA		5,919			5,958			(1	)%		11,292			11,087			2	%		5,464			5,535			(1	)%		16,756			16,622			1	%
ROW		1,190			1,563			(24	)%		2,711			3,289			(18	)%		1,161			1,463			(21	)%		3,872			4,752			(19	)%

Total Diagnostics		37,061			36,403			2	%		71,898			72,072			—	%		35,168			35,305			—	%		107,066			107,377			—	%

Life Science -
Life Science-
North America		5,023			4,311			17	%		9,329			8,562			9	%		4,749			4,737			—	%		14,078			13,299			6	%
EMEA		6,199			4,471			39	%		10,009			8,597			16	%		5,278			5,124			3	%		15,287			13,721			11	%
ROW		1,851			2,080			(11	)%		3,692			3,385			9	%		2,017			1,942			4	%		5,709			5,327			7	%

Total Life Science		13,073			10,862			20	%		23,030			20,544			12	%		12,044			11,803			2	%		35,074			32,347			8	%

Consolidated	$	50,134		$	47,265			6	%	$	94,928		$	92,616			2	%	$	47,212		$	47,108			—	%	$	142,140		$	139,724			2	%

% of total revenues -
% of total revenues-
Diagnostics		74	%		77	%					76	%		78	%					74	%		75	%					75	%		77	%
Life Science		26	%		23	%					24	%		22	%					26	%		25	%					25	%		23	%

Total		100	%		100	%					100	%		100	%					100	%		100	%					100	%		100	%

Ex-North America		30	%		30	%					29	%		28	%					29	%		30	%					29	%		29	%

The revenues generated by each of our reportable segments result primarily from the sale of the following segment-specific categories of products:

Revenue for each product platform/type, as well as its relative percentage of segment revenue, is shown below.


	Three Months Ended March 31,									Six Months Ended March 31,									Three Months Ended June 30,									Nine Months Ended June 30,
	2014			2013			Inc (Dec)			2014			2013			Inc (Dec)			2014			2013			Inc (Dec)			2014			2013			Inc (Dec)
Diagnostics -
Diagnostics-
Molecular	$	9,853		$	8,033			23	%	$	18,348		$	15,427			19	%	$	9,578		$	8,818			9	%	$	27,926		$	24,245			15	%
Immunoassay		27,208			28,370			(4	)%		53,550			56,645			(5	)%		25,590			26,487			(3	)%		79,140			83,132			(5	)%

Total Diagnostics	$	37,061		$	36,403			2	%	$	71,898		$	72,072			—	%	$	35,168		$	35,305			—	%	$	107,066		$	107,377			—	%

Life Science -
Life Science-
Molecular components	$	5,023		$	4,369			15	%	$	9,893		$	8,565			16	%	$	5,476		$	5,158			6	%	$	15,369		$	13,723			12	%
Immunoassay components		8,050			6,493			24	%		13,137			11,979			10	%		6,568			6,645			(1	)%		19,705			18,624			6	%

Total Life Science	$	13,073		$	10,862			20	%	$	23,030		$	20,544			12	%	$	12,044		$	11,803			2	%	$	35,074		$	32,347			8	%

% of Diagnostics revenues -
% of Diagnostics revenues-
Molecular		27	%		22	%					26	%		21	%					27	%		25	%					26	%		23	%
Immunoassay		73	%		78	%					74	%		79	%					73	%		75	%					74	%		77	%

Total Diagnostics		100	%		100	%					100	%		100	%					100	%		100	%					100	%		100	%

% of Life Science revenues -
% of Life Science revenues-
Molecular components		38	%		40	%					43	%		42	%					45	%		44	%					44	%		42	%
Immunoassay components		62	%		60	%					57	%		58	%					55	%		56	%					56	%		58	%

Total Life Science		100	%		100	%					100	%		100	%					100	%		100	%					100	%		100	%

Following is a discussion of the revenues generated by each of these product platforms/types:

We have ~~1,235~~1,265 customer account placements. Of these account placements, ~~just under 1,100~~approximately 1,130 accounts have completed evaluations and validations and are regularly purchasing product, with the balance of our account placements being in some stage of product evaluation and/or validation. Of our account placements, we have approximately ~~250~~275 accounts that are regularly purchasing, evaluating and/or validating two or more assays. Upon receiving FDA clearance on March 25, 2014, we launched ourBordetella pertussis molecular diagnostic test in early April – the most recent test available on ourillumigene molecular testing platform.

We continue to invest in new product development for ourillumigene molecular testing platform, and with the launch of theBordetella pertussis test, now have five commercialized tests on the platform and three additional tests expected to be available for sale in fiscal 2015:

Additionalillumigene tests in early-stage research orand development include enteric parasites such as Giardia, foodborne pathogens such asE. coli, and bloodborne pathogens such as malaria.

We believe that the diagnostic testing market is continuing to move away from culture and immunoassay testing to molecular testing for diseases where there is a favorable cost/benefit position for the total cost of healthcare. While this market is competitive, with molecular companies such as Cepheid and Becton Dickinson and new entrants such as Quidel, Great Basin, Nanosphere, and others, we believe we are well positioned to capitalize on the migration to molecular testing. Our simple, easy-to-use,illumigene platform, with its expanding menu, requires no expensive equipment purchase and little to no maintenance cost. These features, along with its small footprint and the performance of theillumigene assays, makeillumigene an attractive molecular platform to any size ~~hospital.~~hospital or physician office laboratory.

Revenues from our Diagnostics segment’s immunoassay products decreased 4%3% in the ~~second~~third quarter of fiscal 2014 and decreased 5% on a ~~six~~nine month, year-to-date basis. ~~These decreases result~~As described in the product discussions below, the quarterly decrease results primarily from the decline in revenues from ourC. difficile products, partially offset by the revenue growth of ourH. pylori and respiratory products; while the year-to-date decrease results primarily from the decline in revenues from ourC. difficile and respiratory products, partially offset by the revenue growth of ourH. pylori ~~products, as described below.~~products.

During the ~~second~~third quarter of fiscal 2014, revenues from our Life Science segment increased ~~20%~~2%, with revenues from molecular component sales increasing ~~15%~~6% over the comparable fiscal 2013 quarter and revenues from immunoassay component sales ~~increasing 24%~~decreasing 1%. For the first ~~six~~nine months of fiscal 2014, revenues from our Life Science segment increased ~~12%~~8%, with revenues from molecular component sales increasing ~~16%~~12% over the comparable prior year period and revenues from immunoassay component sales increasing ~~10%~~6%. Our molecular component revenues continue to benefit from new product launches and advancements – most notably SensiFAST™ and MyTaq™ PCR components. The fiscal 2014 second quarter revenue level of our bulk immunoassay component business reflects the effect of shipping certain orders during the quarter that were delayed from the fiscal 2014 first quarter, which totaled approximately $1,100.

Revenues from our focus families (C. difficile, foodborne andH. pylori) comprised ~~59%~~63% of our Diagnostics segment’s revenue during ~~both~~ the ~~second~~third quarter of fiscal 2014 and 61% during the first ~~six~~nine months of the fiscal ~~year,~~year. This compared to ~~60%~~65% and 61% during ~~both of~~ the ~~corresponding~~ fiscal 2013 ~~periods.~~quarterly and year-to-date periods, respectively. Following is a discussion of the revenues generated by each product family:

Revenues for ourC. difficile product family ~~declined 6%~~decreased 10% to ~~$9,300~~$8,900 for the fiscal 2014 ~~second~~third quarter, and ~~declined 8%~~decreased 9% to ~~$17,900~~$26,800 for the ~~six~~nine month, year-to-date period. Revenues for ourillumigene product ~~increased 3%~~decreased 5% and ~~were flat~~1% during the three and ~~six~~nine month periods ended ~~March 31,~~June 30, 2014, respectively, ~~while~~and revenues for ourC. difficile immunoassay products ~~declined~~continued to significantly decline as expected. TheC. difficile market has become highly competitive, with over 10 suppliers in the United States. Certain of these suppliers choose to compete solely on price. We believe that two factors will help us respond to these challenging market conditions. First, our marketing programs emphasize that we are the only company that can offer a full range of high performing, FDA cleared,C. difficile testing formats, including toxin, GDH and molecular tests. Second, ourillumigene molecular platform, with its expanding menu, requires no expensive equipment purchase or maintenance contract, which makes it an attractive and affordable option for any size hospital.

Revenues for our foodborne products (Enterohemorrhagic E. coli(“EHEC”) andCampylobacter), all of which are immunoassay products, ~~grew to $5,400~~totaled $5,800 during the fiscal 2014 ~~second~~third quarter, ~~or 1% growth over~~a 5% decrease from the fiscal 2013 ~~second quarter; $11,100 of revenues, or 1% year over year growth, during~~third quarter. During the ~~six~~nine months ended ~~March 31, 2014.~~June 30, 2014, foodborne revenues totaled $16,900, a 1% decrease from the fiscal 2013 year-to-date period. We are once again disappointed in ~~these growth rates~~the results for this product family and ~~have re-emphasized~~are continuing to re-emphasize the benefits of increased sensitivity and faster turnaround time versus culture methods in our marketing programs. While historically the primary competition for our foodborne products has been laboratory culture methods, during 2012 one of our competitors cleared through the FDA a shiga toxin test that competes with our EHEC test. We believe that our test offers better workflow, less hands-on time and quicker results, in addition to being fully CDC-compliant.

During the ~~second~~third quarter of fiscal 2014, revenues from ourH. pylori products, all of which are immunoassay products, ~~grew 11%~~increased 9% to ~~$7,100;~~$7,400; and ~~grew~~increased 10% to ~~$13,600~~$21,000 during the first ~~six~~nine months of fiscal 2014. These increases continue to reflect the benefits of our partnerships with managed care companies in promoting the health and economic benefits of a test and treat strategy, and the ongoing effects of such strategy moving physician behavior away from serology-based testing toward direct antigen testing. A significant amount of theH. pylori product revenues are to reference labs, whose buying patterns may not be consistent period to period.

Total respiratory revenues from our Diagnostics segment ~~decreased 8%~~increased 9% to ~~$5,300~~$3,700 during the fiscal 2014 ~~second~~third quarter; and decreased ~~13%~~8% to ~~$10,100~~$13,800 for the ~~six~~nine month year-to-date period. Contributing to ~~this decreased revenue volume were double digit revenue decreases from~~the quarterly increase was growth in ourillumigene Group A Strep,illumigene Mycoplasma andillumigene Pertussis products. Lower sales of influenza products ~~which reflect a weak influenza season, coupled with a crowded influenza test market.~~contributed to the year-to-date decline in revenue. Partially offsetting the impact of lower influenza product revenues was growth in ~~our~~the aforementioned respiratory-relatedillumigene ~~Group A Strep and~~~~illumi~~~~gene~~ ~~Mycoplasma products, which received FDA approval in September 2012 and June 2013, respectively.~~products.

During the ~~second~~third quarter of fiscal 2014, currency exchange rates had a ~~$200~~$350 favorable impact on revenue; ~~$150~~$200 favorable within the Diagnostics segment and ~~$50~~$150 favorable in the Life Science segment. On a ~~six~~nine month year-to-date basis, currency exchange rates had a ~~$350~~$700 favorable impact on ~~revenue, all of which was~~revenue; $600 favorable within the Diagnostics segment and $100 favorable in the Life Science segment.

Two U.S. distributors accounted for ~~35%~~36% and ~~42%~~40% of our Diagnostics segment’s total revenues for the ~~second~~third quarter of fiscal 2014 and 2013, respectively, and 36% and ~~44%~~43% during the ~~six~~nine months ended ~~March 31,~~June 30, 2014 and 2013, respectively. These ~~revenues~~customers represented 26% and ~~32%~~30% of consolidated revenues for the fiscal 2014 and 2013 ~~second~~third quarters, respectively, and 27% and ~~34%~~33% for the respective year-to-date ~~six~~nine month periods.

Within our Life Science segment, two diagnostic manufacturing customers accounted for ~~23%~~15% and 18% of the segment’s total revenues for the ~~second~~third quarter of fiscal 2014 and 2013, respectively, and ~~17%~~16% and 18% during the ~~six~~nine months ended ~~March 31,~~June 30, 2014 and 2013, respectively.

On January 1, 2013, the medical device tax established as part of the U.S. healthcare reform legislation became effective, and as a result, the Company made its first required tax deposit near the end of January 2013. The Company recorded approximately $450 of medical device tax expense during each of the fiscal 2014 and 2013 ~~second~~third quarters, which is reflected as a component of cost of sales in the accompanying Condensed Consolidated Statements of Operations. During the ~~six~~nine month periods ended ~~March 31,~~June 30, 2014 and 2013, medical device tax expense totaling approximately ~~$900~~$1,350 and ~~$450,~~$900, respectively, was recorded.


	Three Months Ended March 31,									Six Months Ended March 31,									Three Months Ended June 30,									Nine Months Ended June 30,
	2014			2013			Change			2014			2013			Change			2014			2013			Change			2014			2013			Change
Gross Profit	$	31,593		$	30,743			3	%	$	59,600		$	59,539			—	%	$	29,242		$	30,631			(5	)%	$	88,842		$	90,170			(1	)%
Gross Profit Margin		63	%		65	%		-2 points			63	%		64	%		-1 point			62	%		65	%		-3 points			63	%		65	%		-2 points

The overall ~~slight~~ gross profit margin decrease for the three and ~~six~~nine months ended ~~March 31,~~June 30, 2014 primarily results from the combined effects of (i) mix of revenues from the Company’s segments; (ii) mix of products sold; (iii) declines in pricing on selected products; (iv) manufacturing facility utilization; and for the ~~six~~nine month period only ~~(iii)~~(v) the medical device tax, which did not exist during the first quarter of fiscal 2013 (see discussion in Medical Device Tax above).

Our overall operations consist of the sale of diagnostic test kits for various disease states and in alternative test formats, as well as bioresearch reagents, bulk antigens and antibodies, PCR/qPCR reagents, nucleotides, competent cells, proficiency panels, and contract research and development, and contract manufacturing services. Product revenue mix shifts, in the normal course of business, can cause the consolidated gross profit margin to fluctuate by several points.


	Three Months Ended March 31, 2014												Three Months Ended June 30, 2014
	Research & Development			Selling & Marketing			General & Administrative			Total Operating Expenses			Research & Development			Selling & Marketing			General & Administrative			Total Operating Expenses
2013 Expenses	$	2,811		$	5,471		$	7,208		$	15,490		$	2,711		$	5,440		$	6,781		$	14,932

% of Revenues		6	%		12	%		15	%		33	%		6	%		12	%		14	%		32	%
Fiscal 2014 Increases (Decreases):
Diagnostics		434			664			(710	)		388			419			446			93			958
Life Science		(59	)		326			(218	)		49			16			363			(159	)		220

2014 Expenses	$	3,186		$	6,461		$	6,280		$	15,927		$	3,146		$	6,249		$	6,715		$	16,110

% of Revenues		6	%		13	%		13	%		32	%		7	%		13	%		14	%		34	%
% Increase (Decrease)		13	%		18	%		(13	)%		3	%		16	%		15	%		(1	)%		8	%

	Six Months Ended March 31, 2014												Nine Months Ended June 30, 2014
	Research & Development			Selling & Marketing			General & Administrative			Total Operating Expenses			Research & Development			Selling & Marketing			General & Administrative			Total Operating Expenses
2013 Expenses	$	5,328		$	11,164		$	14,703		$	31,195		$	8,039		$	16,604		$	21,484		$	46,127

% of Revenues		6	%		12	%		16	%		34	%		6	%		12	%		15	%		33	%
Fiscal 2014 Increases (Decreases):
Diagnostics		715			883			(463	)		1,135			1,134			1,329			(370	)		2,093
Life Science		(4	)		491			(509	)		(22	)		12			854			(668	)		198

2014 Expenses	$	6,039		$	12,538		$	13,731		$	32,308		$	9,185		$	18,787		$	20,446		$	48,418

% of Revenues		6	%		13	%		14	%		34	%		6	%		13	%		14	%		34	%
% Increase (Decrease)		13	%		12	%		(7	)%		4	%		14	%		13	%		(5	)%		5	%

Overall, total operating ~~expense~~expenses increased during both the ~~second~~third quarter and first ~~six~~nine months of fiscal 2014 relative to the comparable prior fiscal year periods, ~~decreasing~~increasing slightly as a percentage of quarterly and year-to-date consolidated ~~revenues and remaining a consistent percentage of revenues on a year-to-date basis.~~revenues. These levels of operating expenses result in large part from the combined effects of our (i) ongoing efforts to control spending in each of our segments while investing the necessary resources in our strategic areas of growth, including increased investment in Research & Development for our molecular platform products; and (ii) overall decreased incentive compensation expense in light of the decline in corporate-wide operating profits.

Operating expenses for the Diagnostics segment increased ~~$388~~$958 for the ~~second~~third quarter of fiscal 2014 compared to the fiscal 2013 ~~second~~third quarter, and in the first ~~six~~nine months of fiscal 2014, increased ~~$1,135~~$2,093 over the comparable prior year period. These overall increases result largely from the combined effects of (i) currency exchange rates (increases of ~~$50~~$100 and ~~$100~~$200 for the quarter and year-to-date, respectively); and (ii) the following:

Overall increase in spending on new product development activities, related primarily to the previously noted products for ourillumigene molecular platform, as well as immunoassay products in development.

Addition of field sales force personnel, including the filling of open territorial positions, since the prior year quarter, resulting in an approximate ~~$400~~$300 increase in personnel-related expenses on a quarterly basis ($~~600~~900 on a year-to-date basis), along with increased product sample expense of approximately ~~$150 both quarterly and year-to-date.~~$100 for the quarter ($250 year-to-date).

A decrease in bonus ~~and profit sharing expenses~~expense as a result of the previously noted ~~year-to-date~~ decline in corporate-wide operating profits, partially offset by an approximate $100 and ~~$600~~$700 increase in stock-based compensation during the ~~second~~third quarter and first ~~six~~nine months of fiscal 2014, respectively, and other less significant general operating expense increases.

Operating expenses for the Life Science segment increased ~~$49~~$220 and ~~decreased $22~~$198 for the ~~second~~third quarter and first ~~six~~nine months of fiscal 2014, respectively. This activity reflects in large part the net effects of (i) currency exchange rates ~~(decreases~~(increases of ~~$10~~$100 and $50 for the quarter and year-to-date, respectively); (ii) ongoing increased sales and marketing investments; and (iii) decreased bonus expenses resulting from the decline in corporate-wide operating profits.

Operating income ~~increased 3%~~decreased 16% to ~~$15,666~~$13,132 for the ~~second~~third quarter of fiscal 2014, and decreased 4%8% to ~~$27,292~~$40,424 for the first ~~six~~nine months of fiscal 2014, as a result of the factors discussed above.

The effective rate for income taxes was ~~34% for the second quarters of both fiscal 2014 and fiscal 2013, and 34%~~31% and 35% for the ~~six~~third quarter of fiscal 2014 and 2013, respectively, and 33% and 35% for the nine month, year-to-date periods ended ~~March 31,~~June 30, 2014 and 2013, respectively. The lower current year rates primarily result from the positive effects of research credits in certain foreign jurisdictions and a net U.S. foreign tax credit resulting from a recent restructuring of our legal entities. For the fiscal year ending September 30, 2014, we expect the effective tax rate to approximate 34%~~-35%~~.

Our cash flow and financing requirements are determined by analyses of operating and capital spending budgets, consideration of acquisition plans, and consideration of common share dividends. We have historically maintained a credit facility to augment working capital requirements and to respond quickly to acquisition opportunities. Our investment portfolio presently consists of overnight repurchase agreements.

We have an investment policy that guides the holdings of our investment portfolio. Our objectives in managing the investment portfolio are to (i) preserve capital; (ii) provide sufficient liquidity to meet working capital requirements and fund strategic objectives such as acquisitions; and (iii) capture a market rate of return commensurate with market conditions and our policy’s investment eligibility criteria. As we look forward, we will continue to manage the holdings of our investment portfolio with preservation of capital being the primary objective.

We do not expect current conditions in the financial markets, or overall economic conditions, to have a significant impact on our liquidity needs, financial condition, or results of operations, although no assurances can be made in this regard. We intend to continue to fund our working capital requirements and dividends from current cash flows from operating activities and cash on hand. If needed, we also have an additional source of liquidity through our $30,000 bank credit facility. Approximately ~~$3,500~~$3,400 of our accounts receivable at ~~March 31,~~June 30, 2014 is due from Italian hospital customers whose funding ultimately comes from the Italian government, ~~an amount~~ which is ~~consistent with the balance~~down from approximately $3,500 due on such accounts at September 30, 2013. Our liquidity needs may change if overall economic conditions change and/or liquidity and credit within the financial markets tightens for an extended period of time, and such conditions impact the collectibility of our customer accounts receivable or impact credit terms with our vendors, or disrupt the supply of raw materials and services.

Net cash provided by operating activities decreased ~~39%~~27% for the first ~~six~~nine months of fiscal 2014 to ~~$13,556,~~$23,611, reflecting the 5%8% decrease in net earnings, along with the effects of the payment of incentive bonus payments related to fiscal 2013, the timing of federal income tax payments, inventory purchases, and the timing of payments from and to customers and suppliers, respectively. Net cash flows from operating activities and cash on hand are anticipated to be adequate to fund working capital requirements, capital expenditures and dividends during the next 12 months.

We have a $30,000 credit facility with a commercial bank that expires on September 15, 2015. As of ~~April 30,~~July 31, 2014, there were no borrowings outstanding on this facility and we had 100% borrowing capacity available to us. We have had no borrowings outstanding under this facility during the first ~~six~~nine months of fiscal 2014 or during the full year of fiscal 2013.

Our capital expenditures are estimated to range between approximately $5,000 to ~~$7,000~~$6,000 for fiscal 2014, with the actual amount depending upon actual operating results and the phasing of certain projects. Such expenditures may be funded with cash and equivalents on hand, operating cash flows, and/or availability under the $30,000 credit facility discussed above. This range of capital expenditures includes approximately $4,000 related to an expansion of our molecular diagnostic manufacturing capacity in Cincinnati, Ohio.

We do not utilize any special-purpose financing vehicles or have any undisclosed off-balance sheet arrangements.

There have been no material changes in the Company’s exposure to market risk since September 30, 2013.

As of ~~March 31,~~June 30, 2014, an evaluation was completed under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15(b) and 15d-15(b) promulgated under the Securities Exchange Act of 1934, as amended. Based on that evaluation, our management, including the CEO and CFO, concluded that our disclosure controls and procedures were effective as of ~~March 31,~~June 30, 2014. There have been no changes in our internal control over financial reporting identified in connection with the evaluation of internal control that occurred during the ~~second~~third fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting, or in other factors that could materially affect internal control subsequent to ~~March 31,~~June 30, 2014.

There have been no material changes from risk factors as previously disclosed in the Registrant’s Form 10-K in response to Item 1A to Part I of Form 10-K.

The following exhibits are being filed or furnished as a part of this Quarterly Report on Form 10-Q.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


Class		Outstanding ~~April 30,~~July 31, 2014
Common Stock, no par value		~~41,555,911~~ 41,567,521


	Page(s)
PART I. FINANCIAL INFORMATION

Item 1. Financial Statements (Unaudited)

Condensed Consolidated Statements of Operations Three and ~~Six~~Nine Months Ended ~~March 31,~~June 30, 2014 and 2013		1

Condensed Consolidated Statements of Comprehensive Income Three and ~~Six~~Nine Months Ended ~~March 31,~~June 30, 2014 and 2013		2

Condensed Consolidated Statements of Cash Flows ~~Six~~Nine Months Ended ~~March 31,~~June 30, 2014 and 2013		3

Condensed Consolidated Balance Sheets ~~March 31,~~June 30, 2014 and September 30, 2013		4-5

Condensed Consolidated Statement of Changes in Shareholders’ Equity ~~Six~~Nine Months Ended ~~March 31,~~June 30, 2014		6

Notes to Condensed Consolidated Financial Statements		7-12

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		12-20

Item 3. Quantitative and Qualitative Disclosures About Market Risk		2021

Item 4. Controls and Procedures		2021

PART II. OTHER INFORMATION

Item 1A. Risk Factors		21

Item 6. Exhibits		21

Signature		22

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company